Sugi Predict

Sugi Predict / Compounds / SCHEMBL21382268

SCHEMBL21382268

SCHEMBL21382268

CC1(C)OB(c2cc3c(cc2F)NC(=O)CC3)OC1(C)C

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 10/20 0.40
▸ KIF11 P52732 5/20 0.39
▸ CA9 Q16790 1/20 0.38
▸ NPC1 O15118 1/20 0.35
▸ MAPK13 O15264 1/20 0.35
▸ MAPK12 P53778 1/20 0.35
▸ MAPK11 Q15759 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TRPV1 Q8NER1 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320598 1.00 PKM (0.40) PKMKIF11CA9NPC1MAPK13
SCHEMBL17092624 0.87 AHR (0.36) KIF11
SCHEMBL18513605 0.83 PKM (0.38) PKMKIF11CA9NPC1MAPK13
SCHEMBL18513616 0.81 PKM (0.40) PKMKIF11CA9NPC1MAPK13
SCHEMBL30292339 0.80 ALDH1A1 (0.33) —
SCHEMBL25252454 0.77 HSD17B1 (0.35) KMT2A
SCHEMBL4104017 0.75 CA9 (0.52) PKMKIF11CA9NPC1MAPK13
SCHEMBL17042127 0.74 CA9 (0.50) CA9NPC1MAPK13MAPK12MAPK11
SCHEMBL422134 0.74 PDE3B (0.44) PKMKIF11CA9NPC1MAPK13
SCHEMBL18112976 0.74 MMP12 (0.44) PKMKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
US-12139474-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-11-12 — — US disclosed
US-20240002367-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2024-01-04 — — US disclosed
US-11780830-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-10-10 — — US disclosed
US-11702407-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-07-18 — — US disclosed
EP-4161936-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-04-12 — — EP disclosed
CN-115867556-A LPA receptor antagonists and uses thereof 吉利德科学公司 2023-03-28 — — CN disclosed
US-20210380561-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2021-12-09 — — US disclosed
US-20210317110-A1 TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2021-10-14 — — US disclosed
US-10995086-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-05-04 — — US disclosed
EP-3768675-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Yuhan Corporation (KR) 2021-01-27 — — EP disclosed
CN-111886233-A Novel triazolone derivative or salt thereof and pharmaceutical composition comprising the same 柳韩洋行 2020-11-03 — — CN disclosed
US-20190322655-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-10-24 — — US disclosed
WO-2019180646-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-09-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702407-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 PKM 2306/4885KIF11 3320/4885CA9 4703/4885
US-20190322655-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME SLC10A1, VAPB, VAT1 PKM 2759/4885KIF11 2075/4885CA9 4716/4885
US-20210317110-A1 TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME SLC10A1, VAT1, LIPC PKM 2223/4885KIF11 2239/4885CA9 4640/4885
US-12139474-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 PKM 2280/4885KIF11 3264/4885CA9 4657/4885
US-11780830-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same SLC10A1, VAT1, LIPC PKM 2223/4885KIF11 2239/4885CA9 4640/4885
US-10995086-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same SLC10A1, VAT1, VAPB PKM 2345/4885KIF11 2215/4885CA9 4644/4885
US-20240002367-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 PKM 2280/4885KIF11 3264/4885CA9 4657/4885
US-20210380561-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 PKM 2306/4885KIF11 3320/4885CA9 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.